Overview

NCI Definition: A diffusely infiltrating, WHO grade III astrocytoma with focal or dispersed anaplasia, and a marked proliferative potential. It may arise from a low-grade astrocytoma, but it can also be diagnosed at first biopsy, without indication of a less malignant precursor lesion. It has an intrinsic tendency for malignant progression to glioblastoma. (WHO) [1]

Anaplastic astrocytomas most frequently harbor alterations in TP53, IDH1, ATRX, EGFR, and CDKN2A [2].

Most Commonly Altered Genes in Anaplastic Astrocytoma

TP53 Mutation, IDH1 Mutation, IDH1 Codon 132 Missense, TP53 c.217-c.1178 Missense, and TP53 c.142-c.212 Missense are the most common alterations in anaplastic astrocytoma [2].

Top Alterations in Anaplastic Astrocytoma

Significant Genes in Anaplastic Astrocytoma

ABL2 +

ACVR1B +

APC +

ASXL1 +

ATM +

ATR +

BLM +

BRCA1 +

BRCA2 +

CDK12 +

CDKN1A +

CDKN1B +

CDKN2A +

CHD4 +

CYLD +

DICER1 +

DNMT3A +

EGFR +

ERBB2 +

ERBB3 +

EZH2 +

FGF1 +

FGF10 +

FGF11 +

FGF12 +

FGF13 +

FGF14 +

FGF16 +

FGF17 +

FGF18 +

FGF19 +

FGF2 +

FGF20 +

FGF21 +

FGF22 +

FGF23 +

FGF3 +

FGF4 +

FGF5 +

FGF6 +

FGF7 +

FGF8 +

FGF9 +

FGFR1 +

FGFR2 +

FGFR3 +

FGFR4 +

FLT3 +

GATA3 +

H3F3A +

HGF +

IDH1 +

IDH2 +

KDM6A +

KDR +

KEAP1 +

KIT +

KMT2D +

KRAS +

MAGI2 +

MAP3K1 +

MED12 +

MET +

MGMT +

MSH2 +

MSH6 +

MYC +

NF1 +

NF2 +

NOTCH1 +

NOTCH2 +

NRAS +

NSD1 +

PIK3C2B +

PIK3CA +

PIK3CB +

PIK3R1 +

PTCH1 +

PTPN11 +

RB1 +

RUNX1 +

SETD2 +

SMARCA4 +

SOX9 +

STAG2 +

TAF1 +

TBX3 +

TET2 +

TP53 +

XPO1 +

Disease Details

Synonyms
Malignant Astrocytoma, Grade III Astrocytoma, High-grade astrocytoma, NOS, ASTROCYTOMA, ANAPLASTIC, MALIGNANT, Grade III Astrocytic Tumor, Grade III Astrocytic Neoplasm
Parent(s)
WHO Grade III Glioma
OncoTree Name
Anaplastic Astrocytoma
OncoTree Code
AASTR

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 4. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.